HI
ALNY icon

Harbour Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Harbour Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.1K Sell
150
-1
-0.7% -$302 ﹤0.01% 2446
2026
Q1 		$50.1K Buy
151
+35
+30% +$11.9K ﹤0.01% 2339
2025
Q4 		$46.1K Sell
116
-11
-9% -$4.87K ﹤0.01% 2004
2025
Q3 		$57.9K Buy
127
+31
+32% +$12.6K ﹤0.01% 1834
2025
Q2 		$31.3K Buy
96
+5
+5% +$1.38K ﹤0.01% 2027
2025
Q1 		$24.6K Sell
91
-42
-32% -$10.8K ﹤0.01% 2096
2024
Q4 		$31.3K Buy
133
+2
+2% +$526 ﹤0.01% 1929
2024
Q3 		$36K Buy
131
+5
+4% +$1.3K ﹤0.01% 1820
2024
Q2 		$30.6K Buy
126
+24
+24% +$3.79K ﹤0.01% 1770
2024
Q1 		$15.2K Sell
102
-8
-7% -$1.33K ﹤0.01% 2068
2023
Q4 		$21.1K Buy
110
+57
+108% +$9.71K ﹤0.01% 1850
2023
Q3 		$9.39K Buy
53
+6
+13% +$1.15K ﹤0.01% 2049
2023
Q2 		$8.93K Buy
47
+2
+4% +$397 ﹤0.01% 2085
2023
Q1 		$9.01K Buy
45
+4
+10% +$841 ﹤0.01% 2052
2022
Q4 		$9.74K Buy
+41
New +$8.74K ﹤0.01% 1963

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's ALNY Position: Q2 2026 in Review

Harbour Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.66% in Q2 2026, selling an estimated $302 and leaving 150 shares worth $45.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Harbour Investments first reported a position in ALNY in Q4 2022 and has held it in 15 quarters since. The position peaked at $57.9K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Harbour Investments held 150 shares of Alnylam Pharmaceuticals worth $45.1K as of Q2 2026.
  • Harbour Investments sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2446 holding.
  • Harbour Investments first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Harbour Investments's Alnylam Pharmaceuticals position peaked at $57.9K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.